

2020 Fourth Quarter Financial and Corporate Update FEBRUARY 9, 2021 -

.

100

1270

ED (23

1

100

-

FORWARD-LOOKING STATEMENTS

Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: our opportunities for growth and diversification, including the expected timing of decisions with respect to NDA, sNDA, BLA, and MAA and other regulatory submissions outside of the U.S. for Jakafi, retifanlimab, tafasitamab, pemigatinib, Olumiant and ruxolitinib cream and whether those submissions will be approved and the expected timing of an sNDA submission for ruxolitinib cream for vitiligo; expectations with respect to Jakafi growth and potential growth drivers; the potential impacts of the COVID-19 pandemic and measures taken to address the pandemic on our business, operations and financial results, including expectations regarding effects on commercial operations and clinical trials; expectations regarding the commercialization of Monjuvi and Pemazyre; expectations regarding the commercial launch of and establishment of commercial operations for ruxolitinib cream; expectations regarding the submission for regulatory approval of parsaclisib in non-Hodgkin lymphoma and for ruxolitinib cream, Tabrecta and Jakavi in additional indications; expectations regarding the receipt or presentation of clinical trial results for various of our and our collaborative partners' product candidates; expectations regarding the initiation or completion of clinical trials for various of our product candidates; the potential for product candidates in our LIMBER program, including their potential for and timing of regulatory approval and expected patent exclusivity; expectations regarding the initiation of clinical trials for tafasitamab; the expected development strategy and potential for retifanlimab; our 2021 GAAP and Non-GAAP financial guidance and expectations underlying that guidance; and our expectations regarding 2021 newsflow items.

These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the actual time required by the regulatory authorities to review submissions for regulatory approval of Jakafi, retifanlimab, tafasitamab, pemigatinib, Olumiant and ruxolitinib cream and the results of such reviews; unanticipated delays, including unanticipated delays in the submission for regulatory approval of parsaclisib in non-Hodgkin lymphoma and for ruxolitinib cream, Tabrecta and Jakavi in additional indications; the effects of the COVID-19 pandemic and measures to address the pandemic on our clinical trials, supply chain and other third-party providers, sales and marketing efforts, and business, development and discovery operations as well as on regulatory agencies such as the FDA; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; our dependence on relationships with and changes in the plans and expenditures of our collaboration partners; the efficacy or safety of our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products and the products of our collaboration partners; sales, manufacturing and distribution requirements, including our and our collaboration partners; and bility to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our quarterly report on Form 10-Q fo



FOURTH QUARTER AND YEAR-END REVIEW

HERVÉ HOPPENOT – CEO




150

1000

1

(33)

STRENGTH ACROSS ENTIRE PORTFOLIO FUELS GROWTH





Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are registered trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys.

1. Monjuvi revenues recognized by MorphoSys and included in our collaboration loss sharing line item on our condensed consolidated statement of operations in our fourth quarter and full year 2020 financial results press release issued on February 9, 2021. 2. Totals may not add due to rounding. 3. FY 2020 total revenues includes \$205m of milestone payments.

OPPORTUNITIES FOR GROWTH AND DIVERSIFICATION

SEVEN SUBMISSIONS SEEKING APPROVAL, ALL WITH DECISIONS DUE IN 2021

MPNs and GVHD	LIMBER development progressing (PI3Kδ, BET, ALK2, CK0804 ¹) sNDA submitted for Jakafi [®] in steroid-refractory chronic GVHD	
	Successful launches of Monjuvi [®] and Pemazyre [®] Multiple trials in preparation evaluating tafasitamab combinations	
Hematology/Oncology	Immuno-oncology pipeline (incl. PD-L1, CD137xPD-L1, AXL/MER, A _{2A} /A _{2B} ,) progressing BLA submitted for retifanlimab in SCAC; MAA submitted for tafasitamab in DLBCL; CHMP+ opinion and J-NDA submitted for pemigatinib in CCA	
Dermatology	NDA submitted (with PRV) for ruxolitinib cream in atopic dermatitis Pivotal trials in vitiligo fully recruited Highly experienced commercial dermatology team being assembled	
Royalties	Olumiant [®] approved in atopic dermatitis in EU and Japan; sNDA submitted to FDA Tabrecta [®] approved in NSCLC in US and Japan	



Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are registered trademarks of Novartis (Tabrecta) and Lilly (Olumiant). Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys. GVHD = graft-versus-host disease; SCAC = squamous cell anal carcinoma; CCA = cholangiocarcinoma; NSCLC = non-small cell lung cancer. PRV = priority review voucher. 1. Development of CK0804 in combination with ruxolitinib in collaboration with Cellenkos.

U.S. COMMERCIAL UPDATE

BARRY FLANNELLY - GENERAL MANAGER, NORTH AMERICA



63

100

1


(INCO)

100

150

-

PATIENT DEMAND DRIVING JAKAFI® GROWTH





FY2020 sales \$1.94 billion

- Excellent Jakafi performance in 2020
 - Robust patient demand across MF, PV and GVHD
 - > Total number of patients on therapy continues to grow
 - > Partial recovery in new patient growth seen in Q3 and Q4


Strong outlook for 2021:

- Acceleration of growth expected in H2
 - > Continued recovery of new patient starts
 - > Anticipated approval in steroid-refractory chronic GVHD
- Ongoing COVID-19 impact in H1

LAUNCH OF PEMAZYRE® PROGRESSING WELL

DURATION OF THERAPY DRIVING PERFORMANCE

Percent dispenses by Repeat/New Patients






FY2020 sales \$26 million

- ~300 prescribers since launch
 - >65% prescribers are community-based oncologists
- Testing for FGFR2+ alterations continues to increase <u>Of oncologists surveyed¹</u>:
 - > >90% report testing patients prior to 2L therapy selection
 - > ~65% report testing patients prior to 1L therapy selection







Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). ORR = overall response rate; CR = complete responders; NR = not reached; DLBCL = diffuse-large B-cell lymphoma.

1. Monjuvi revenues recognized by MorphoSys and included in our collaboration loss sharing line item on our condensed consolidated statement of operations in our fourth quarter and full year 2020 financial results press release issued on February 9, 2021.

RUXOLITINIB CREAM: PLANNING FOR LAUNCH


FDA DECISION FOR ATOPIC DERMATITIS EXPECTED MID-YEAR

Promotional focus at launch

- ~5.5 million AD patients age 12+ receive Rx treatment
- High unmet need: Only 22% of patients report AD is controlled with current treatment
- Initial uptake of ruxolitinib cream expected to be by specialists in medical dermatology and allergy
 - > ~11,000 specialty targets identified
 - Targets cover 80% of market TRx¹

High-impact dermatology team being assembled

- ~150 FTEs anticipated in field force (sales & medical)²
- Full recruitment expected by mid-April





CLINICAL DEVELOPMENT

STEVEN STEIN – CHIEF MEDICAL OFFICER



1

(North

150

-

 63

SIGNIFICANT CLINICAL PROGRESS IN 2020

MPNs and GVHD

- ✓ Jakafi[®]: REACH3 results in SR chronic GVHD; sNDA submitted
- LIMBER: once-a-day ruxolitinib development progressing
- ✓ **LIMBER:** ruxolitinib+parsaclisib PoC data in MF
- ✓ **LIMBER:** ruxolitinib+parsaclisib Phase 3 program underway
- LIMBER: PoC trials underway for INCB57643 (BET) and INCB00928 (ALK2)

Hematology/Oncology

- ✓ Monjuvi®: FDA approval in r/r DLBCL; MAA for tafasitamab submitted
- Pemazyre[®]: FDA approval and CHMP+ opinion in CCA; J-NDA submitted
- ✓ retifanlimab: POD1UM-202 results in advanced SCAC; NDA submitted
- ✓ parsaclisib: CITADEL results in NHL

Dermatology


- ruxolitinib cream: NDA submitted in atopic dermatitis
- ruxolitinib cream: Phase 3 program in vitiligo fully recruited
- ✓ **INCB54707:** Preliminary efficacy and safety data in hidradenitis suppurativa

Royalties

- ✓ **Tabrecta®:** FDA and Japanese approval in METex14 NSCLC
- ✓ Olumiant[®]: EU and Japanese approval in AD; Phase 2 data in alopecia areata




Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Tabrecta) and Lilly (Olumiant). Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys. Retifanlimab licensed from MacroGenics. GVHD = graft-versus-host disease; MF = myelofibrosis; DLBCL = diffuse large B-cell lymphoma; CCA = cholangiocarcinoma; SCAC = squamous cell anal carcinoma; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; AD = atopic dermatitis.





Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are registered trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). cGVHD = chronic graft-versus-host disease.

LIMBER: OPPORTUNITIES FOR GROWTH IN MPNs & GVHD



2. Development of CK0804 plus ruxolitinib in collaboration with Cellenkos

TAFASITAMAB: MULTIPLE TRIALS INITIATING IN 2021

	front MIND	inMIND		
Phase/Indication	Phase 3 in 1L DLBCL	Phase 3 in r/r FL & MZL	POC in NHL	POC in NHL
# patients	~900	~600	NA	NA
Drug Arms	Tafasitamab + LEN + R-CHOP	Tafasitamab + LEN + rituximab (R ²) vs	Tafasitamab + parsaclisib	Tafasitamab + LEN + plamotamab ¹
	R-CHOP	LEN + rituximab (R ²)		
Primary Endpoint	PFS	PFS	Safety	Safety

2 pivotal trials and 2 POC studies to start in 2021



Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. PFS = progression-free survival. LEN = lenalidomide. 1. In collaboration with and sponsored by Xencor.

DEVELOPMENT STRATEGY FOR RETIFANLIMAB

Retifanlimab (PD-1)

BLA under FDA review for SCAC PDUFA date of July 25, 2021

POD1UM-202 in SCAC

- ORR of 14%; median DOR of 9.5m
- Responses observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ infection status

Registration-directed trials ongoing in:

- Merkel cell carcinoma (monotherapy)
- MSI-high endometrial (monotherapy)
- NSCLC (combination therapy)

INCB81776 (AXL/MER)


- Dual AXL/MER inhibition expected to impair oncogenic effects of TAM kinases
- Potential for synergistic activity with PD-1 axis blockade
- Clinical data expected 2021


Favata et al, AACR 2018 [TGI = tumor growth inhibition]

– INCB106385 (A_{2A} / A_{2B})

Previously unpublished data on file, Incyte

- Strategy to inhibit multiple nodes within adenosine pathway
- Triple inhibition (w/ PD-1 and CD73) offers maximal potential benefit
- IND for anti-CD73 MAb expected 2021







FINANCIAL RESULTS

CHRISTIANA STAMOULIS – CFO



63

100

(North

NON-GAAP ADJUSTMENTS

- Management has chosen to present financial highlights for the quarter and year ended December 31, 2020 and 2019 on both a GAAP and Non-GAAP basis in the belief that this Non-GAAP information is useful for investors.
- Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company's business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company's core operations.
- The Company believes these adjustments are useful to investors by providing an enhanced understanding
 of the financial performance of the Company's core operations. The metrics have been adopted to align the
 Company with disclosures provided by industry peers.





FINANCIAL HIGHLIGHTS: REVENUES


\$ millions	Q4 2020 GAAP	Q4 2019 GAAP	YoY Change	FY 2020 GAAP	FY 2019 GAAP	YoY Change
Net product revenues	559	491	14%	2,069	1,775	17%
Jakafi	517	466	11%	1,938	1,685	15%
Iclusig	29	24	18%	105	90	17%
Pemazyre	14	-	NM	26	-	NM
Royalties	120	89	35%	393	306	28%
Jakavi	87	65	34%	278	226	23%
Olumiant	31	24	31%	111	80	38%
Tabrecta	2	-	NM	4	-	NM
Total product and royalty revenues	680	579	17%	2,462	2,081	18%
Milestone and contract revenue	110	-	NM	205	78	NM
Total revenues	790	579	36 %	2,667	2,159	24%



FINANCIAL HIGHLIGHTS: OPERATING EXPENSES

\$ millions	Q4 2020 GAAP	Q4 2019 GAAP	YoY Change	FY 2020 GAAP	FY 2019 GAAP	YoY Change
COGS	36	32	13%	131	114	15%
R&D	406	313	30%	2,216	1,154	92%
R&D – ongoing	380	310	23%	1,240	1,126	10%
R&D – upfront and milestones	26	3	NM	976	28	NM
SG&A	167	136	23%	517	469	10%
Collaboration loss sharing	12	-	NM	43	-	NM

REVENUE GROWTH EXCEEDS EXPENSE GROWTH





FINANCIAL GUIDANCE: FULL YEAR 2021

	FY 2021 GAAP	FY 2021 Non-GAAP ¹
Net product revenues		
Jakafi	\$2,125 – \$2,200 million	\$2,125 – \$2,200 million
Other Hematology/Oncology (Iclusig in EU and Pemazyre in U.S.)	\$145 – \$160 million	\$145 – \$160 million

Product revenue guidance does not include revenue from any potential new product launches.

Costs and expenses		
COGS	6 – 7% net product revenues	5 – 6% net product revenues
R&D	\$1,350 – \$1,390 million	\$1,220 – \$1,250 million
SG&A	\$735 – \$775 million	\$665 – \$700 million

GAAP and Non-GAAP SG&A expense guidance for 2021 includes costs to support the potential launches of ruxolitinib cream as a treatment for atopic dermatitis in the U.S., pemigatinib as a treatment for cholangiocarcinoma in the EU and Japan, and tafasitamab as a treatment for DLBCL in the EU.



2021 OUTLOOK

HERVÉ HOPPENOT – CEO



5

0

-

 100

1

63

.

IMPORTANT UPDATES EXPECTED IN 2021

H1 2021

H2 2021

MPNs and GVHD	LIMBER: QD ruxolitinib BA/BE data	Jakafi®: FDA decision (SR chronic GVHD) LIMBER: JAK+BET PoC trial to begin
Hematology/ Oncology	<pre>tafasitamab: frontMIND to begin (P3, 1L DLBCL) tafasitamab: inMIND to begin (P3, r/r FL & MZL) ✓ pemigatinib: MAA decision (r/r CCA)</pre>	LIMBER: JAK+ALK2 PoC trial to begin tafasitamab: MAA decision (r/r DLBCL) parsaclisib: NDA submission (r/r NHL) retifanlimab: FDA decision (SCAC)
	pemigatinib : PMDA decision (r/r CCA ¹)	INCB86550: clinical efficacy & safety data
Dermatology	<pre>ruxolitinib cream: TRuE-V data (P3, vitiligo) ruxolitinib cream: FDA decision (atopic dermatitis)</pre>	<pre>ruxolitinib cream: sNDA submission (vitiligo) ruxolitinib cream: MAA submission (vitiligo)</pre>
Royalties	Olumiant®: FDA decision (atopic dermatitis) Olumiant®: BRAVE-AA data (P3, alopecia areata)	Olumiant®: BRAVE data (P3, lupus)



Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys.

1. PMDA decision for pemigatinib in FGFR2 fusion positive locally advanced or metastatic biliary tract cancer.

FINANCIAL BACK-UP SLIDES



FINANCIAL HIGHLIGHTS: FOURTH QUARTER

\$ millions	Q4 2020 GAAP	Q4 2019 GAAP	Q4 2020 Non-GAAP ¹	Q4 2019 Non-GAAP ¹
Net product revenues	559	491	559	491
Jakafi	517	466	517	466
Iclusig	29	24	29	24
Pemazyre	14	-	14	-
Royalties	120	89	120	89
Jakavi	87	65	87	65
Olumiant	31	24	31	24
Tabrecta	2	-	2	-
Total product and royalty revenues	680	579	680	579
Milestone and contract revenue	110	-	110	-
Total revenues	790	579	790	579
Costs and expenses	625	484	571	434
COGS	36	32	31	27
R&D	406	313	376	284
R&D – ongoing	380	310	350	281
R&D – upfront and milestones	26	3	26	3
SG&A	167	136	152	123
Contingent consideration	4	3	-	-
Collaboration loss sharing	12	-	12	-
Operating income	164	95	218	146
Operating income excluding revenues and R&D expense related to upfront and milestones	80	98	134	149



Totals may not add due to rounding

1. Non-GAAP costs and expenses exclude stock-based compensation and other expenses; a reconciliation from GAAP to Non-GAAP financial measures is provided on slide 28.

FINANCIAL HIGHLIGHTS: FULL YEAR 2020

\$ millions	FY 2020 GAAP	FY 2019 GAAP	FY 2020 Non-GAAP ¹	FY 2019 Non-GAAP ¹
Net product revenues	2,069	1,775	2,069	1,775
Jakafi	1,938	1,685	1,938	1,685
Iclusig	105	90	105	90
Pemazyre	26	0	26	0
Royalties	393	306	393	306
Jakavi	278	226	278	226
Olumiant	111	80	111	80
Tabrecta	4	-	4	-
Total product and royalty revenues	2,462	2,081	2,462	2,081
Milestone and contract revenue	205	78	205	78
Total revenues	2,667	2,159	2,667	2,159
Costs and expenses	2,930	1,757	2,708	1,549
COGS	131	114	109	92
R&D	2,216	1,154	2,096	1,040
R&D – ongoing	1,240	1,126	1,120	1,012
R&D – upfront and milestones	976	28	976	28
SG&A	517	469	460	417
Contingent consideration	23	20	-	-
Collaboration loss sharing	43	-	43	-
Operating income (loss)	(264)	402	(41)	610
Operating income excluding revenues and R&D expense				
related to upfront and milestones	507	353	730	560



Totals may not add due to rounding

1. Non-GAAP costs and expenses exclude stock-based compensation and other expenses; a reconciliation from GAAP to Non-GAAP financial measures is provided on slide 28.

2020 AND 2019 NON-GAAP RECONCILIATION

\$ millions	Q4 2020	Q4 2019	FY 2020	FY 2019
GAAP operating income (loss)	164	95	(264)	402
Adjustments				
Non-cash stock compensation from equity awards	45	42	178	167
Amortization of acquired product rights	5	5	22	22
Change in fair value of contingent consideration	4	3	23	20
Non-GAAP operating income (loss)	218	146	(41)	610



2021 FINANCIAL GUIDANCE NON-GAAP RECONCILIATION

	GAAP Guidance	Adjustments	Non-GAAP Guidance
Net product revenues			
Jakafi	\$2,125 – \$2,200 million	-	\$2,125 – \$2,200 million
Other Hematology/Oncology	\$145 – \$160 million	-	\$145 – \$160 million
Costs and expenses			
COGS	6 – 7% net product revenues	Amortization of acquired product rights for Iclusig and stock-based compensation	5 – 6% net product revenues
R&D	\$1,350 – \$1,390 million	Stock-based compensation (\$130 - \$140 million)	\$1,220 – \$1,250 million
SG&A	\$735 – \$775 million	Stock-based compensation (\$70 - \$75 million)	\$665 – \$700 million





8

070

ED (22

-

-

1

(

-

-

ir@incyte.com
investor.incyte.com